Several small molecules, for example lapatinib (targeting EGFR and HER2; [156]), afatinib (targeting EGFR and HER2; [157]) and others (reviewed in [153]), have shown some promise in the treatment of HNSCC. This evidence concerns the gene ERBB2 and head and neck squamous cell carcinoma.